U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sanders GD, Lowenstern A, Borre E, et al. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Oct. (Comparative Effectiveness Reviews, No. 214.)

Cover of Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update [Internet].

Show details

Appendix CList of Included Studies

*Denotes 2017 update

  1. *Abraham JM, Larson J, Chung MK, et al. Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation?. Am J Med 2013;126(12):1143.e1–8. PMID: 24139523. [PMC free article: PMC3883047] [PubMed: 24139523]
  2. *Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology 2017;152(5):1014–1022.e1. PMID: 28043907. [PubMed: 28043907]
  3. *Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Bmj 2015;350:h1857. PMID: 25910928. [PMC free article: PMC4413863] [PubMed: 25910928]
  4. *Abumuaileq RR, Abu-Assi E, Lopez-Lopez A, et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2015;15:156. PMID: 26584938. [PMC free article: PMC4653932] [PubMed: 26584938]
  5. Ad N, Henry L, Schlauch K, et al. The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation. Ann Thorac Surg. 2010;90(4):1257–62. PMID: 20868824. [PubMed: 20868824]
  6. *Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm 2017;23(9):968–978. Digital Object Identifier: 10.18553/jmcp.2017.23.9.968. PMID: 28854073. [PMC free article: PMC10398327] [PubMed: 28854073] [CrossRef]
  7. *Alexander JH, Andersson U, Lopes RD, et al. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2016;1(6):673–81. PMID: 27463942. [PubMed: 27463942]
  8. *Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014;35(4):224–32. PMID: 24144788. [PubMed: 24144788]
  9. *Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34(31):2464–71. PMID: 23594592. [PubMed: 23594592]
  10. *Allan V, Banerjee A, Shah AD, et al. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. Heart 2017;103(3):210–218. PMID: 27580623. [PMC free article: PMC5284481] [PubMed: 27580623]
  11. *Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013;61(17):1790–8. PMID: 23500276. [PubMed: 23500276]
  12. *Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current Medical Research and Opinion 2017;33(9):1595–1604. Digital Object Identifier: 10.1080/03007995.2017.1345729. [PubMed: 28635338] [CrossRef]
  13. *Amin A, Keshishian A, Vo L, et al. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ 2017;1–10. Digital Object Identifier: 10.1080/13696998.2017.1394866. PMID: 29047304. [PubMed: 29047304] [CrossRef]
  14. *An J, Niu F, Zheng C, et al. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm 2017;23(6):700–712. PMID: 28530526. [PMC free article: PMC10398296] [PubMed: 28530526]
  15. *Apostolakis S, Guo Y, Lane DA, et al. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 2013;34(46):3572–9. PMID: 23966309. [PubMed: 23966309]
  16. *Apostolakis S, Lane DA, Buller H, et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost 2013;110(5):1074–9. PMID: 24048467. [PubMed: 24048467]
  17. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation: The AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol. 2012:60(9):861–7. PMID: 22858389. [PubMed: 22858389]
  18. *Ashburner JM, Go AS, Chang Y, et al. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol 2016;67(3):239–47. PMID: 26796386. [PMC free article: PMC4724056] [PubMed: 26796386]
  19. Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med. 2005;20(11):1008–13. PMID: 16307625. [PMC free article: PMC1490253] [PubMed: 16307625]
  20. *Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2015;132(8):624–32. PMID: 26106009. [PubMed: 26106009]
  21. *Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2015;8(6):593–9. PMID: 26508666. [PubMed: 26508666]
  22. Azoulay L, Dell’aniello S, Simon TA, et al. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord. 2012;12(1):49. PMID: 22734842. [PMC free article: PMC3444325] [PubMed: 22734842]
  23. *Azoulay L, Dell’Aniello S, Simon T, et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013;109(3):431–9. PMID: 23306435. [PubMed: 23306435]
  24. *Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2017;103(8):623–628. PMID: 27798052. [PMC free article: PMC5529964] [PubMed: 27798052]
  25. *Banerjee A, Fauchier L, Bernard-Brunet A, et al. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2014;111(3):549–56. PMID: 24452108. [PubMed: 24452108]
  26. *Banerjee A, Fauchier L, Vourc’h P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013;61(20):2079–87. PMID: 23524209. [PubMed: 23524209]
  27. *Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J 2015;170(4):675–682.e8. PMID: 26386791. [PubMed: 26386791]
  28. *Barnes GD, Gu X, Haymart B, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Thromb Res 2014;134(2):294–9. PMID: 24929840. [PubMed: 24929840]
  29. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?. Stroke. 2007;38(9):2459–63. PMID: 17673721. [PubMed: 17673721]
  30. *Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One 2018;13(1):e0191592. Digital Object Identifier: 10.1371/journal.pone.0191592. PMID: 29370229. [PMC free article: PMC5784935] [PubMed: 29370229] [CrossRef]
  31. *Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016;37(38):2882–2889. PMID: 27357359. [PMC free article: PMC5070447] [PubMed: 27357359]
  32. Beinart R, Heist EK, Newell JB, et al. Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(1):10–5. PMID: 20662984. [PubMed: 20662984]
  33. *Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol 2017;69(6):868–876. PMID: 27889397. [PMC free article: PMC5411320] [PubMed: 27889397]
  34. Berge E, Abdelnoor M, Nakstad PH, et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355(9211):1205–10. PMID: 10770301. [PubMed: 10770301]
  35. *Beyer-Westendorf J, Ehlken B and Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 2016;18(8):1150–7. PMID: 26830891. [PubMed: 26830891]
  36. *Bjorck F, Renlund H, Lip GY, et al. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiol 2016;1(2):172–80. PMID: 27437888. [PubMed: 27437888]
  37. *Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016;134(1):24–36. PMID: 27358434. [PubMed: 27358434]
  38. *Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64(23):2471–82. PMID: 25500231. [PubMed: 25500231]
  39. *Bonde AN, Lip GY, Kamper AL, et al. Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study. Stroke 2016;47(11):2707–2713. PMID: 27758943. [PubMed: 27758943]
  40. *Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord 2017;17(1):236. Digital Object Identifier: 10.1186/s12872-017-0671-6. PMID: 28865440. [PMC free article: PMC5581418] [PubMed: 28865440] [CrossRef]
  41. *Bouillon K, Bertrand M, Maura G, et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2015;2(4):e15E0–9. PMID: 26687957. [PubMed: 26687957]
  42. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371(9609):315–21. PMID: 18294998. [PubMed: 18294998]
  43. *Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol 2015;196:127–31. PMID: 26093161. [PubMed: 26093161]
  44. *Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35(47):3377–85. PMID: 25148838. [PMC free article: PMC4265383] [PubMed: 25148838]
  45. *Breithardt G, Baumgartner H, Berkowitz SD, et al. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart 2016;102(13):1036–43. PMID: 26888572. [PMC free article: PMC4941167] [PubMed: 26888572]
  46. *Brown JD, Shewale AR and Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. J Manag Care Spec Pharm 2017;23(9):958–967. Digital Object Identifier: 10.18553/jmcp.2017.23.9.958. PMID: 28854077. [PMC free article: PMC5747360] [PubMed: 28854077] [CrossRef]
  47. *Brown JD, Shewale AR and Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naive Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm 2016;22(11):1319–1329. PMID: 27783556. [PMC free article: PMC5751430] [PubMed: 27783556]
  48. Bunch TJ, Crandall BG, Weiss JP, et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol. 2009;20(9):988–93. PMID: 19473299. [PubMed: 19473299]
  49. Burton C, Isles C, Norrie J, et al. The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J Gen Pract. 2006;56(530):697–702. PMID: 16954003. [PMC free article: PMC1876637] [PubMed: 16954003]
  50. Cafolla A, Campanelli M, Baldacci E, et al. Oral anticoagulant therapy in Italian patients 80 yr of age or older with atrial fibrillation: A pilot study of low vs. standard PT/INR targets. Eur J Haematol. 2012;89(1):81–86. PMID: 22519759. [PubMed: 22519759]
  51. *Camm AJ, Accetta G, Al Mahmeed W, et al. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open 2017;7(3):e014579. PMID: 28264833. [PMC free article: PMC5353285] [PubMed: 28264833]
  52. *Chrischilles EA, Gagne JJ, Fireman B, et al. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiol Drug Saf 2018. Digital Object Identifier: 10.1002/pds.4375. PMID: 29318683. [PubMed: 29318683] [CrossRef]
  53. *Chun KR, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Heart Rhythm 2013;10(12):1792–9. PMID: 23973952. [PubMed: 23973952]
  54. *Coleman C, Yuan Z, Schein J, et al. Importance of balancing follow-up time and impact of oral-anticoagulant users’ selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Curr Med Res Opin 2017;33(6):1033–1043. Digital Object Identifier: 10.1080/03007995.2017.1297932. PMID: 28366075. [PubMed: 28366075] [CrossRef]
  55. *Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin 2016;32(12):2047–2053. PMID: 27633045. [PubMed: 27633045]
  56. *Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation-The RELIEF study. Int J Cardiol 2016;203:882–4. PMID: 26605688. [PubMed: 26605688]
  57. *Coleman CI, Peacock WF and Antz M. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients with Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Heart Lung Circ 2017. PMID: 28528780. [PubMed: 28528780]
  58. *Coleman CI, Peacock WF, Bunz TJ, et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke 2017;48(8):2142–2149. Digital Object Identifier: 10.1161/strokeaha.117.017474. PMID: 28655814. [PubMed: 28655814] [CrossRef]
  59. *Coleman CI, Tangirala M and Evers T. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. PLoS One 2016;11(6):e0157769. PMID: 27327275. [PMC free article: PMC4915663] [PubMed: 27327275]
  60. *Collings SL, Vannier-Moreau V, Johnson ME, et al. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France. Arch Cardiovasc Dis 2018. Digital Object Identifier: 10.1016/j.acvd.2017.10.003. PMID: 29398546. [PubMed: 29398546] [CrossRef]
  61. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12. PMID: 16765759. [PubMed: 16765759]
  62. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. PMID: 21309657. [PubMed: 21309657]
  63. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. PMID: 19717844. [PubMed: 19717844]
  64. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78. PMID: 19336502. [PubMed: 19336502]
  65. *Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 2013;128(3):237–43. PMID: 23770747. [PubMed: 23770747]
  66. *Coppens M, Synhorst D, Eikelboom JW, et al. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. Eur Heart J 2014;35(28):1856–63. PMID: 24569032. [PubMed: 24569032]
  67. *Cowper PA, Sheng S, Lopes RD, et al. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2017;2(5):525–534. PMID: 28355434. [PMC free article: PMC5814979] [PubMed: 28355434]
  68. Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol. 2009;32(8):981–6. PMID: 19659615. [PubMed: 19659615]
  69. *De Caterina R, Andersson U, Alexander JH, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J 2016;175:175–83. PMID: 27179738. [PubMed: 27179738]
  70. *Deambrosis P, Bettiol A, Bolcato J, et al. Real-practice thromboprophylaxis in atrial fibrillation. Acta Pharm 2017;67(2):227–236. PMID: 28590907. [PubMed: 28590907]
  71. *Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin 2016;32(3):573–82. PMID: 26652179. [PubMed: 26652179]
  72. *Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin 2017;33(10):1745–1754. Digital Object Identifier: 10.1080/03007995.2017.1334638. PMID: 28849676. [PubMed: 28849676] [CrossRef]
  73. *Deitelzweig S, Luo X, Gupta K, et al. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm 2017;23(11):1191–1201. Digital Object Identifier: 10.18553/jmcp.2017.17060. PMID: 29083968. [PMC free article: PMC10397614] [PubMed: 29083968] [CrossRef]
  74. *Denas G, Gennaro N, Ferroni E, et al. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naive patients with non-valvular atrial fibrillation: Propensity score matched cohort study. Int J Cardiol 2017;249:198–203. Digital Object Identifier: 10.1016/j.ijcard.2017.09.029. PMID: 28935464. [PubMed: 28935464] [CrossRef]
  75. *DeVore AD, Hellkamp AS, Becker RC, et al. Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace 2016;18(8):1135–42. PMID: 27174904. [PMC free article: PMC4974633] [PubMed: 27174904]
  76. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–63. PMID: 21059484. [PubMed: 21059484]
  77. Diener HC, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11(3):225–31. PMID: 22305462. [PubMed: 22305462]
  78. Doucet J, Greboval-Furstenfeld E, Tavildari A, et al. Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. Fundam Clin Pharmacol. 2008;22(5):569–74. PMID: 18844728. [PubMed: 18844728]
  79. *Douros A, Renoux C, Coulombe J, et al. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. Pharmacoepidemiology and Drug Safety 2017;26(12):1546–1554. Digital Object Identifier: 10.1002/pds.4333. [PubMed: 28984052] [CrossRef]
  80. *Durheim MT, Cyr DD, Lopes RD, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol 2016;202:589–94. PMID: 26447668. [PubMed: 26447668]
  81. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–11. PMID: 22572202. [PubMed: 22572202]
  82. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429–35. PMID: 22818021. [PubMed: 22818021]
  83. *Eikelboom JW, Connolly SJ, Hart RG, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol 2013;62(10):900–8. PMID: 23770182. [PubMed: 23770182]
  84. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72. PMID: 21576658. [PubMed: 21576658]
  85. *Eisen A, Giugliano RP, Ruff CT, et al. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J 2016;172:144–51. PMID: 26856226. [PubMed: 26856226]
  86. *Esteve-Pastor MA, Garcia-Fernandez A, Macias M, et al. Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. Circ J 2016;80(10):2102–8. PMID: 27557850. [PubMed: 27557850]
  87. *Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost 2017;117(10):1848–1858. Digital Object Identifier: 10.1160/th17-07-0478. PMID: 28799620. [PubMed: 28799620] [CrossRef]
  88. *Ezekowitz JA, Lewis BS, Lopes RD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother 2015;1(2):86–94. PMID: 27533976. [PubMed: 27533976]
  89. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419–26. PMID: 17950801. [PubMed: 17950801]
  90. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401. PMID: 21757117. [PMC free article: PMC3175766] [PubMed: 21757117]
  91. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51(8):810–5. PMID: 18294564. [PMC free article: PMC3534960] [PubMed: 18294564]
  92. *Fanola CL, Giugliano RP, Ruff CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J 2017;38(12):888–896. PMID: 28064150. [PubMed: 28064150]
  93. *Fauchier L, Clementy N, Bisson A, et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. Stroke 2016;47(7):1831–6. PMID: 27231269. [PubMed: 27231269]
  94. *Figini F, Mazzone P, Regazzoli D, et al. Left atrial appendage closure: A single center experience and comparison of two contemporary devices. Catheter Cardiovasc Interv 2017;89(4):763–772. PMID: 27567013. [PubMed: 27567013]
  95. *Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012;43(12):3291–7. PMID: 23033347. [PubMed: 23033347]
  96. *Fonseca E, Sander SD, Hess GP, et al. Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin. J Manag Care Spec Pharm 2015;21(11):1039–53. PMID: 26521116. [PMC free article: PMC10397811] [PubMed: 26521116]
  97. *Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;134(1):37–47. PMID: 27358435. [PubMed: 27358435]
  98. *Forslund T, Wettermark B, Andersen M, et al. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace 2017. PMID: 28177459. [PubMed: 28177459]
  99. *Forslund T, Wettermark B and Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol 2016;72(3):329–38. PMID: 26613954. [PubMed: 26613954]
  100. *Forslund T, Wettermark B, Wandell P, et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol 2014;70(12):1477–85. PMID: 25219360. [PubMed: 25219360]
  101. Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J. 2012;163(4):720–8. PMID: 22520540. [PubMed: 22520540]
  102. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94. PMID: 21873708. [PubMed: 21873708]
  103. *Fraenkel L, Street RL, Jr., Towle V, et al. A pilot randomized controlled trial of a decision support tool to improve the quality of communication and decision-making in individuals with atrial fibrillation. J Am Geriatr Soc 2012;60(8):1434–41. PMID: 22861171. [PMC free article: PMC3419306] [PubMed: 22861171]
  104. *Friberg L, Benson L and Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015;36(5):297–306. PMID: 24722803. [PubMed: 24722803]
  105. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10. PMID: 22246443. [PubMed: 22246443]
  106. Frost L, Johnsen SP, Pedersen L, et al. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med. 2002;252(1):64–9. PMID: 12074740. [PubMed: 12074740]
  107. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70. PMID: 11401607. [PubMed: 11401607]
  108. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9. PMID: 16504638. [PubMed: 16504638]
  109. Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(2):312–8. PMID: 22319005. [PubMed: 22319005]
  110. *Geller BJ, Giugliano RP, Braunwald E, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J 2015;170(4):669–74. PMID: 26386790. [PubMed: 26386790]
  111. *Giner-Soriano M, Roso-Llorach A, Vedia Urgell C, et al. Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. Pharmacoepidemiol Drug Saf 2017;26(1):97–107. PMID: 27868275. [PubMed: 27868275]
  112. *Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093–104. PMID: 24251359. [PubMed: 24251359]
  113. *Giugliano RP, Ruff CT, Rost NS, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke 2014;45(8):2372–8. PMID: 24947287. [PubMed: 24947287]
  114. *Gloekler S, Shakir S, Doblies J, et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol 2015;104(8):656–65. PMID: 25736061. [PubMed: 25736061]
  115. *Go AS, Singer DE, Toh S, et al. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med 2017;167(12):845–854. Digital Object Identifier: 10.7326/m16-1157. PMID: 29132153. [PubMed: 29132153] [CrossRef]
  116. *Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014;63(9):891–900. PMID: 24315894. [PMC free article: PMC4206565] [PubMed: 24315894]
  117. *Gorst-Rasmussen A, Lip GY and Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016;25(11):1236–1244. PMID: 27229855. [PubMed: 27229855]
  118. *Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131(2):157–64. PMID: 25359164. [PubMed: 25359164]
  119. *Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016;176(11):1662–1671. PMID: 27695821. [PubMed: 27695821]
  120. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. PMID: 21870978. [PubMed: 21870978]
  121. *Guimaraes PO, Wojdyla DM, Alexander JH, et al. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol 2017;227:443–449. PMID: 27852444. [PubMed: 27852444]
  122. *Gupta DK, Giugliano RP, Ruff CT, et al. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr 2016;29(6):537–44. PMID: 27106009. [PMC free article: PMC4893881] [PubMed: 27106009]
  123. *Haas S, Ten Cate H, Accetta G, et al. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One 2016;11(10):e0164076. PMID: 27792741. [PMC free article: PMC5085020] [PubMed: 27792741]
  124. *Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;130(2):138–46. PMID: 24895454. [PubMed: 24895454]
  125. *Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35(28):1864–72. PMID: 24561548. [PMC free article: PMC4104493] [PubMed: 24561548]
  126. *Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017;3(1):28–36. PMID: 27680880. [PMC free article: PMC5216196] [PubMed: 27680880]
  127. Hammerstingl C, Schmitz A, Fimmers R, et al. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther. 2009;27(4):230–8. PMID: 19903186. [PubMed: 19903186]
  128. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–322. PMID: 22402056. [PubMed: 22402056]
  129. *Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014;45(5):1304–12. PMID: 24743444. [PubMed: 24743444]
  130. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41. PMID: 20837828. [PubMed: 20837828]
  131. Hart RG, Bhatt DL, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008;25(4):344–7. PMID: 18303254. [PubMed: 18303254]
  132. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511–7. PMID: 22492518. [PubMed: 22492518]
  133. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343–8. PMID: 22700854. [PubMed: 22700854]
  134. Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39(5):1482–6. PMID: 18323500. [PubMed: 18323500]
  135. *Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 2015;36(20):1264–72. PMID: 25499871. [PubMed: 25499871]
  136. *Hernandez I, Zhang Y and Saba S. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Am J Cardiol 2017;120(10):1813–1819. Digital Object Identifier: 10.1016/j.amjcard.2017.07.092. PMID: 28864318. [PubMed: 28864318] [CrossRef]
  137. *Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2016;1(4):451–60. PMID: 27438322. [PubMed: 27438322]
  138. *Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. American Heart Journal 2018. Digital Object Identifier: 10.1016/j.ahj.2017.10.015. [PubMed: 29653640] [CrossRef]
  139. *Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129(9):961–70. PMID: 24323795. [PubMed: 24323795]
  140. *Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. American Heart Journal 2018. Digital Object Identifier: 10.1016/j.ahj.2017.10.015. [PubMed: 29653640] [CrossRef]
  141. *Hijazi Z, Lindahl B, Oldgren J, et al. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc 2017;6(6). Digital Object Identifier: 10.1161/jaha.116.004851. PMID: 28645934. [PMC free article: PMC5669148] [PubMed: 28645934] [CrossRef]
  142. *Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37(20):1582–90. PMID: 26920728. [PMC free article: PMC4875560] [PubMed: 26920728]
  143. *Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016;387(10035):2302–11. PMID: 27056738. [PubMed: 27056738]
  144. *Hilkens NA, Algra A and Greving JP. Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation. Stroke 2017;48(11):3142–3144. Digital Object Identifier: 10.1161/strokeaha.117.019183. PMID: 28931618. [PubMed: 28931618] [CrossRef]
  145. Hobbs FD, Roalfe AK, Lip GY, et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ. 2011;342:d3653. PMID: 21700651. [PMC free article: PMC3121229] [PubMed: 21700651]
  146. *Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost 2018. Digital Object Identifier: 10.1160/th17-10-0733. PMID: 29359278. [PubMed: 29359278] [CrossRef]
  147. *Hohnloser SH, Basic E and Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol 2017. PMID: 28293797. [PubMed: 28293797]
  148. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012:33(22):2821–2830. PMID: 22933567. [PubMed: 22933567]
  149. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–76. PMID: 22215856. [PubMed: 22215856]
  150. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50(22):2156–61. PMID: 18036454. [PubMed: 18036454]
  151. *Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014;64(1):1–12. PMID: 24998121. [PubMed: 24998121]
  152. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–42. PMID: 19683639. [PubMed: 19683639]
  153. *Hu PT, Lopes RD, Stevens SR, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc 2017;6(1). PMID: 28096100. [PMC free article: PMC5523640] [PubMed: 28096100]
  154. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–26. PMID: 12968085. [PubMed: 12968085]
  155. *Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014;63(20):2141–7. PMID: 24657685. [PubMed: 24657685]
  156. *Inohara T, Shrader P, Pieper K, et al. Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA Cardiol 2017. Digital Object Identifier: 10.1001/jamacardio.2017.4665. PMID: 29128866. [PMC free article: PMC5833527] [PubMed: 29128866] [CrossRef]
  157. Jacobs LG, Billett HH, Freeman K, et al. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009;7(3):159–66. PMID: 19616184. [PubMed: 19616184]
  158. *Jain R, Fu AC, Lim J, et al. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. J Manag Care Spec Pharm 2018;24(1):73–82. Digital Object Identifier: 10.18553/jmcp.2018.24.1.73. PMID: 29290177. [PMC free article: PMC10398022] [PubMed: 29290177] [CrossRef]
  159. *Jaspers Focks J, van Vugt SP, Albers-Akkers MT, et al. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. J Thromb Haemost 2016;14(9):1715–24. PMID: 27172860. [PubMed: 27172860]
  160. *Johnson ME, Lefevre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open 2016;6(9):e011471. PMID: 27678530. [PMC free article: PMC5051466] [PubMed: 27678530]
  161. *Jun M, James MT, Ma Z, et al. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis 2017;69(6):734–743. PMID: 27998624. [PubMed: 27998624]
  162. Kiviniemi T, Karjalainen P, Pietila M, et al. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2012;110(1):30–35. PMID: 22464216. [PubMed: 22464216]
  163. *Kochar A, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clin Cardiol 2018;41(1):39–45. Digital Object Identifier: 10.1002/clc.22846. PMID: 29389037. [PMC free article: PMC6489762] [PubMed: 29389037] [CrossRef]
  164. Kwak JJ, Pak HN, Jang JK, et al. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21(6):620–5. PMID: 20039992. [PubMed: 20039992]
  165. Lahtela H, Rubboli A, Schlitt A, et al. Heparin Bridging vs. Uninterrupted Oral Anticoagulation in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting. Circ J. 2012;76(6):1363–1368. PMID: 22447005. [PubMed: 22447005]
  166. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–74. PMID: 22305113. [PubMed: 22305113]
  167. *Laliberte F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther 2015;37(3):554–62. PMID: 25749196. [PubMed: 25749196]
  168. *Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30(7):1317–25. PMID: 24650301. [PubMed: 24650301]
  169. *Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc 2017;6(2). PMID: 28196815. [PMC free article: PMC5523754] [PubMed: 28196815]
  170. Lane DA, Kamphuisen PW, Minini P, et al. Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest. 2011;140(1):146–55. PMID: 21415134. [PubMed: 21415134]
  171. *Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014;127(7):650–656.e5. PMID: 24530792. [PubMed: 24530792]
  172. *Larsen TB, Lip GY, Skjoth F, et al. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes 2012;5(3):335–42. PMID: 22534406. [PubMed: 22534406]
  173. *Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med 2014;127(12):1172–8.e5. PMID: 25193361. [PubMed: 25193361]
  174. *Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in ‘real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014;127(4):329–336.e4. Digital Object Identifier: 10.1016/j.amjmed.2013.12.005. PMID: 24361757. [PubMed: 24361757] [CrossRef]
  175. *Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Bmj 2016;353:i3189. PMID: 27312796. [PMC free article: PMC4910696] [PubMed: 27312796]
  176. *Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015;4(4). PMID: 25862791. [PMC free article: PMC4579955] [PubMed: 25862791]
  177. *Lauw MN, Eikelboom JW, Coppens M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart 2017;103(13):1015–1023. PMID: 28213368. [PubMed: 28213368]
  178. *Lee CJ, Pallisgaard JL, Olesen JB, et al. Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation. J Am Coll Cardiol 2017;69(24):2901–2909. PMID: 28619189. [PubMed: 28619189]
  179. *Lee R, Vassallo P, Kruse J, et al. A randomized, prospective pilot comparison of 3 atrial appendage elimination techniques: Internal ligation, stapled excision, and surgical excision. Journal of Thoracic and Cardiovascular Surgery 2016;152(4):1075–1080. [PubMed: 27422360]
  180. *Leef G, Qin D, Althouse A, et al. Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis. Pacing Clin Electrophysiol 2015;38(11):1310–6. PMID: 26171564. [PubMed: 26171564]
  181. *Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One 2018;13(1):e0191722. Digital Object Identifier: 10.1371/journal.pone.0191722. PMID: 29373602. [PMC free article: PMC5786316] [PubMed: 29373602] [CrossRef]
  182. *Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017;117(6):1072–1082. PMID: 28300870. [PMC free article: PMC6291856] [PubMed: 28300870]
  183. *Lin J, Trocio J, Gupta K, et al. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. J Med Econ 2017:1–10. PMID: 28604139. [PubMed: 28604139]
  184. Lind M, Fahlen M, Kosiborod M, et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res. 2012;129(1):32–5. PMID: 21851969. [PubMed: 21851969]
  185. *Link MS, Giugliano RP, Ruff CT, et al. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol 2017;10(1). PMID: 28077507. [PubMed: 28077507]
  186. Lip GY, Banerjee A, Lagrenade I, et al. Assessing the Risk of Bleeding in Patients with Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Circ Arrhythm Electrophysiol. 2012:5(5):941–8. PMID: 22923275. [PubMed: 22923275]
  187. *Lip GY, Connolly S, Yusuf S, et al. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circ Arrhythm Electrophysiol 2013;6(1):31–8. PMID: 23390125. [PubMed: 23390125]
  188. *Lip GY, Eikelboom J, Yusuf S, et al. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Stroke 2014;45(7):2127–30. PMID: 24916911. [PubMed: 24916911]
  189. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173–80. PMID: 21111555. [PubMed: 21111555]
  190. Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731–8. PMID: 20966417. [PubMed: 20966417]
  191. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. PMID: 19762550. [PubMed: 19762550]
  192. *Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract 2016;70(9):752–63. PMID: 27550177. [PMC free article: PMC5129572] [PubMed: 27550177]
  193. *Lip GY, Skjoth F, Nielsen PB, et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015;114(4):826–34. PMID: 26223245. [PubMed: 26223245]
  194. *Lip GY, Skjoth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65(14):1385–94. PMID: 25770314. [PubMed: 25770314]
  195. *Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis. Thrombosis and Haemostasis 2016;116(5):975–986. [PubMed: 27538358]
  196. *Lip GYH, Skjoth F, Nielsen PB, et al. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. JAMA Cardiol 2017. PMID: 28614582. [PMC free article: PMC5710590] [PubMed: 28614582]
  197. *Lip GYH, Skjoth F, Nielsen PB, et al. The HAS-BLED, ATRIA and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. Am J Med 2017. Digital Object Identifier: 10.1016/j.amjmed.2017.11.046. PMID: 29274754. [PubMed: 29274754] [CrossRef]
  198. *Loo SY, Coulombe J, Dell’Aniello S, et al. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open 2018;8(1):e019638. Digital Object Identifier: 10.1136/bmjopen-2017-019638. PMID: 29371284. [PMC free article: PMC5786093] [PubMed: 29371284] [CrossRef]
  199. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749–58. PMID: 23036896. [PubMed: 23036896]
  200. *Lopes RD, Guimaraes PO, Kolls BJ, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood 2017;129(22):2980–2987. PMID: 28356246. [PubMed: 28356246]
  201. Lorenzoni R, Lazzerini G, Cocci F, et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J. 2004;148(1):e6. PMID: 15215815. [PubMed: 15215815]
  202. Maegdefessel L, Schlitt A, Faerber J, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich). 2008;103(9):628–32. PMID: 18813885. [PubMed: 18813885]
  203. *Magnani G, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail 2016;18(9):1153–61. PMID: 27349698. [PubMed: 27349698]
  204. *Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 2014;35(4):233–41. PMID: 24132190. [PMC free article: PMC3896862] [PubMed: 24132190]
  205. *Mahaffey KW, Wojdyla D, Hankey GJ, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158(12):861–8. PMID: 23778903. [PubMed: 23778903]
  206. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503. PMID: 17693178. [PubMed: 17693178]
  207. Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008;134(3):559–67. PMID: 18641090. [PubMed: 18641090]
  208. *Mar Contreras Muruaga MD, Vivancos J, Reig G, et al. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Comp Eff Res 2017. PMID: 28353372. [PubMed: 28353372]
  209. *Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013;128(20):2192–201. PMID: 24016454. [PubMed: 24016454]
  210. *Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115(1):31–9. PMID: 26246112. [PubMed: 26246112]
  211. *Maura G, Blotiere PO, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015;132(13):1252–60. PMID: 26199338. [PMC free article: PMC4885525] [PubMed: 26199338]
  212. *Mavaddat N, Roalfe A, Fletcher K, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke 2014;45(5):1381–6. PMID: 24692475. [PubMed: 24692475]
  213. *McAlister FA, Wiebe N, Jun M, et al. Are Existing Risk Scores for Nonvalvular Atrial Fibrillation Useful for Prediction or Risk Adjustment in Patients With Chronic Kidney Disease?. Can J Cardiol 2017;33(2):243–252. PMID: 27956042. [PubMed: 27956042]
  214. *McHorney CA, Peterson ED, Laliberte F, et al. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation. Clin Ther 2016;38(11):2477–2488. Digital Object Identifier: 10.1016/j.clinthera.2016.09.014. PMID: 27789043. [PubMed: 27789043] [CrossRef]
  215. *McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013;6(3):451–60. PMID: 23575255. [PubMed: 23575255]
  216. *Melloni C, Dunning A, Granger CB, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. Am J Med 2017;130(12):1440–1448.e1. Digital Object Identifier: 10.1016/j.amjmed.2017.06.026. PMID: 28739198. [PubMed: 28739198] [CrossRef]
  217. *Mikkelsen AP, Lindhardsen J, Lip GY, et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012;10(9):1745–51. PMID: 22805071. [PubMed: 22805071]
  218. *Monaco L, Biagi C, Conti V, et al. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2017;83(7):1532–1543. PMID: 28071818. [PMC free article: PMC5465343] [PubMed: 28071818]
  219. *Monz BU, Connolly SJ, Korhonen M, et al. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 2013;168(3):2540–7. PMID: 23664436. [PubMed: 23664436]
  220. Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37–41. PMID: 19062079. [PubMed: 19062079]
  221. *Mueller T, Alvarez-Madrazo S, Robertson C, et al. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Pharmacoepidemiol Drug Saf 2017;26(11):1378–1386. Digital Object Identifier: 10.1002/pds.4272. PMID: 28752670. [PMC free article: PMC5697642] [PubMed: 28752670] [CrossRef]
  222. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–6. PMID: 21200007. [PubMed: 21200007]
  223. Nair CK, Holmberg MJ, Aronow WS, et al. Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography. Am J Ther. 2009;16(5):385–92. PMID: 19955857. [PubMed: 19955857]
  224. *Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014;30(12):2461–9. PMID: 24926732. [PubMed: 24926732]
  225. *Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2015;31(10):1831–40. Digital Object Identifier: 10.1185/03007995.2015.1074064. PMID: 26211816. [PubMed: 26211816] [CrossRef]
  226. *Ng KH, Shestakovska O, Connolly SJ, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing 2016;45(1):77–83. PMID: 26590293. [PubMed: 26590293]
  227. *Nielsen PB, Larsen TB, Skjoth F, et al. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep 2016;6:27410. PMID: 27265586. [PMC free article: PMC4893655] [PubMed: 27265586]
  228. *Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Bmj 2017;356:j510. PMID: 28188243. [PMC free article: PMC5421446] [PubMed: 28188243]
  229. *Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017;17(1):238. Digital Object Identifier: 10.1186/s12872-017-0672-5. PMID: 28874129. [PMC free article: PMC5585896] [PubMed: 28874129] [CrossRef]
  230. *Noseworthy PA, Yao X, Abraham NS, et al. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest 2016;150(6):1302–1312. PMID: 27938741. [PubMed: 27938741]
  231. *O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36(46):3258–64. PMID: 26424865. [PMC free article: PMC4670965] [PubMed: 26424865]
  232. *O’Donnell MJ, Eikelboom JW, Yusuf S, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J 2016;178:145–50. PMID: 27502862 [PubMed: 27502862]
  233. *O’Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationdagger. Eur Heart J 2015;36(23):1470–7. PMID: 25687352. [PubMed: 25687352]
  234. Oldgren J, Alings M, Darius H, et al. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. Ann Intern Med. 2011;155(10):660–667. PMID: 22084332. [PubMed: 22084332]
  235. *Oldgren J, Hijazi Z, Lindback J, et al. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation 2016;134(22):1697–1707. PMID: 27569438. [PubMed: 27569438]
  236. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. PMID: 21282258. [PMC free article: PMC3031123] [PubMed: 21282258]
  237. Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012;141(1):147–53. PMID: 21680645. [PubMed: 21680645]
  238. Olesen JB, Lip GY, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med. 2012;125(8):826e13–23. PMID: 22579139. [PubMed: 22579139]
  239. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739–49. PMID: 21789337. [PubMed: 21789337]
  240. Olesen JB, Lip GYH, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9(8):1460–1467. PMID: 21624047 [PubMed: 21624047]
  241. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost. 2012;107(6):1172–9. PMID: 22473219. [PubMed: 22473219]
  242. *Orgel R, Wojdyla D, Huberman D, et al. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes 2017;10(5). PMID: 28495674. [PMC free article: PMC5485838] [PubMed: 28495674]
  243. *Orkaby AR, Ozonoff A, Reisman JI, et al. Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. J Am Geriatr Soc 2017;65(2):249–256. PMID: 28039854. [PubMed: 28039854]
  244. *Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc 2017;6(12). Digital Object Identifier: 10.1161/jaha.117.007034. PMID: 29220330. [PMC free article: PMC5779022] [PubMed: 29220330] [CrossRef]
  245. *Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013;61(6):651–8. PMID: 23391196. [PubMed: 23391196]
  246. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. PMID: 21830957. [PubMed: 21830957]
  247. *Peacock WF, Tamayo S, Patel M, et al. CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Ann Emerg Med 2017;69(5):541–550.e1. PMID: 27913059. [PubMed: 27913059]
  248. *Perera KS, Pearce LA, Sharma M, et al. Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). Am J Cardiol 2017. Digital Object Identifier: 10.1016/j.amjcard.2017.11.028. PMID: 29291887. [PubMed: 29291887] [CrossRef]
  249. *Phelps E, Delate T, Witt DM, et al. Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. Thromb Res 2018;163:54–59. Digital Object Identifier: 10.1016/j.thromres.2018.01.024. PMID: 29407629. [PubMed: 29407629] [CrossRef]
  250. *Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016;115(5):1056–63. PMID: 26843425. [PubMed: 26843425]
  251. *Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014;3(2):e000521. PMID: 24755148. [PMC free article: PMC4187517] [PubMed: 24755148]
  252. *Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 2015;12(7):1501–7. PMID: 25778430. [PubMed: 25778430]
  253. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. PMID: 20299623. [PubMed: 20299623]
  254. *Pokorney SD, Piccini JP, Stevens SR, et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Assoc 2016;5(3):e002197. PMID: 26955859. [PMC free article: PMC4943233] [PubMed: 26955859]
  255. Poli D, Antonucci E, Grifoni E, et al. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost. 2009;101(5):938–42. PMID: 19404548. [PubMed: 19404548]
  256. Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009;101(2):367–72. PMID: 19190823. [PubMed: 19190823]
  257. Poli D, Lip GY, Antonucci E, et al. Stroke risk stratification in a “real-world” elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol. 2011;22(1):25–30. PMID: 20653814. [PubMed: 20653814]
  258. Poli D, Testa S, Antonucci E, et al. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011;140(4):918–24. PMID: 21511826. [PMC free article: PMC3734882] [PubMed: 21511826]
  259. Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012;5(2):319–26. PMID: 22319004. [PubMed: 22319004]
  260. *Proietti M and Lip GY. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. Am J Med 2016;129(10):1110–6. PMID: 27086494. [PubMed: 27086494]
  261. *Proietti M and Lip GYH. Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. Int J Cardiol 2018;252:96–100. Digital Object Identifier: 10.1016/j.ijcard.2017.10.091. PMID: 29249444. [PubMed: 29249444] [CrossRef]
  262. *Proietti M, Hijazi Z, Andersson U, et al. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. J Intern Med 2017. Digital Object Identifier: 10.1111/joim.12702. PMID: 29044861. [PubMed: 29044861] [CrossRef]
  263. *Proietti M, Senoo K, Lane DA, et al. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep 2016;6:24376. PMID: 27067661. [PMC free article: PMC4828703] [PubMed: 27067661]
  264. *Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med 2017. Digital Object Identifier: 10.1016/j.amjmed.2017.10.036. PMID: 29122636. [PubMed: 29122636] [CrossRef]
  265. Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151–6. PMID: 17175564. [PubMed: 17175564]
  266. *Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017;70(24):2964–2975. Digital Object Identifier: 10.1016/j.jacc.2017.10.021. PMID: 29103847. [PubMed: 29103847] [CrossRef]
  267. *Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127(6):720–9. PMID: 23325525. [PubMed: 23325525]
  268. *Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. Jama 2014;312(19):1988–98. PMID: 25399274. [PubMed: 25399274]
  269. *Renoux C, Coulombe J and Suissa S. Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. Eur Heart J 2017;38(19):1473–1479. PMID: 28073863. [PubMed: 28073863]
  270. *Reynolds SL, Ghate SR, Sheer R, et al. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. Health Qual Life Outcomes 2017;15(1):128. Digital Object Identifier: 10.1186/s12955-017-0705-x. PMID: 28637460. [PMC free article: PMC5480105] [PubMed: 28637460] [CrossRef]
  271. Rietbrock S, Heeley E, Plumb J, et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57–64. PMID: 18585497. [PubMed: 18585497]
  272. Rietbrock S, Plumb JM, Gallagher AM, et al. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost. 2009;101(3):527–34. PMID: 19277415. [PubMed: 19277415]
  273. *Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Sci Rep 2017;7(1):12066. Digital Object Identifier: 10.1038/s41598-017-11683-2. PMID: 28935868. [PMC free article: PMC5608893] [PubMed: 28935868] [CrossRef]
  274. *Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores. J Am Heart Assoc 2017;6(7). Digital Object Identifier: 10.1161/jaha.117.006490. PMID: 28729407. [PMC free article: PMC5586327] [PubMed: 28729407] [CrossRef]
  275. *Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clin Ther 2018;40(1):114–122. Digital Object Identifier: 10.1016/j.clinthera.2017.11.014. PMID: 29275065. [PubMed: 29275065] [CrossRef]
  276. Roldan V, Marin F, Fernandez H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a ‘real world’ anticoagulated atrial fibrillation population. Chest. 2012. PMID: 22722228. [PubMed: 22722228]
  277. *Rost NS, Giugliano RP, Ruff CT, et al. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke 2016;47(8):2075–82. PMID: 27387994. [PubMed: 27387994]
  278. *Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385(9984):2288–95. PMID: 25769361. [PubMed: 25769361]
  279. *Ruff CT, Giugliano RP, Braunwald E, et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol 2016;1(9):999–1006. PMID: 27706467. [PubMed: 27706467]
  280. *Ruff CT, Giugliano RP, Braunwald E, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2014;64(6):576–84. PMID: 25104527. [PubMed: 25104527]
  281. Ruiz Ortiz M, Romo E, Mesa D, et al. [Predicting embolic events in patients with nonvalvular atrial fibrillation: evaluation of the CHADS2 score in a Mediterranean population]. Rev Esp Cardiol. 2008;61(1):29–35. PMID: 18221688. [PubMed: 18221688]
  282. Ruiz Ortiz M, Romo E, Mesa D, et al. Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome. Cardiology. 2010;115(3):200–4. PMID: 20160440. [PubMed: 20160440]
  283. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51(8):818–25. PMID: 18294566. [PubMed: 18294566]
  284. Ruiz-Nodar JM, Marin F, Manzano-Fernandez S, et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest. 2011;139(6):1402–9. PMID: 20864616 [PubMed: 20864616]
  285. Ruiz-Nodar JM, Marin F, Roldan V, et al. Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score? Circ Cardiovasc Interv. 2012;5(4):459–66. PMID: 22787018. [PubMed: 22787018]
  286. Saad EB, Costa IP, Costa RE, et al. Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin. Arq Bras Cardiol. 2011;97(4):289–296. PMID: 21861038. [PubMed: 21861038]
  287. Sam C, Massaro JM, D’Agostino RB, Sr., et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol. 2004;94(7):947–51. PMID: 15464686. [PubMed: 15464686]
  288. *Schmid M, Gloekler S, Saguner AM, et al. Transcatheter left atrial appendage closure in patients with atrial fibrillation. Kardiovaskulare Medizin 2013;16(4):123–130.
  289. *Seeger JD, Bykov K, Bartels DB, et al. Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. Drug Safety 2017;40(2):169–181. [PubMed: 27900668]
  290. *Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015;114(6):1277–89. PMID: 26446507. [PubMed: 26446507]
  291. *Senoo K, Proietti M, Lane DA, et al. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med 2016;129(6):600–7. PMID: 26482233. [PubMed: 26482233]
  292. *Shah R, Hellkamp A, Lokhnygina Y, et al. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. Am Heart J 2016;179:77–86. PMID: 27595682. [PubMed: 27595682]
  293. *Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv 2018;2(3):200–209. Digital Object Identifier: 10.1182/bloodadvances.2017010694. PMID: 29378726. [PMC free article: PMC5812321] [PubMed: 29378726] [CrossRef]
  294. *Sherwood MW, Cyr DD, Jones WS, et al. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. JACC Cardiovasc Interv 2016;9(16):1694–702. PMID: 27539689. [PMC free article: PMC6921699] [PubMed: 27539689]
  295. *Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol 2015;66(21):2271–81. PMID: 26610874. [PubMed: 26610874]
  296. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362–7. PMID: 15331796. [PubMed: 15331796]
  297. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130(5):1390–6. PMID: 17099015. [PubMed: 17099015]
  298. *Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013;2(3):e000250. PMID: 23782923. [PMC free article: PMC3698792] [PubMed: 23782923]
  299. *Singh-Franco D, Hale G and Jacobs RJ. Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. Hosp Pract (1995) 2017;1–8. Digital Object Identifier: 10.1080/21548331.2018.1415621. PMID: 29224408. [PubMed: 29224408] [CrossRef]
  300. *Sjogren V, Bystrom B, Renlund H, et al. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS One 2017;12(7):e0181000. Digital Object Identifier: 10.1371/journal.pone.0181000. PMID: 28700711. [PMC free article: PMC5507293] [PubMed: 28700711] [CrossRef]
  301. Snipelisky D, Kauffman C, Prussak K, et al. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012:35(1):29–33. PMID: 22869389. [PubMed: 22869389]
  302. *Song X, Gandhi P, Gilligan AM, et al. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin. Expert Rev Pharmacoecon Outcomes Res 2017;1–10. Digital Object Identifier: 10.1080/14737167.2017.1347041. PMID: 28649894. [PubMed: 28649894] [CrossRef]
  303. *Staerk L, Fosbol EL, Lip GYH, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2017;38(12):907–915. PMID: 27742807. [PubMed: 27742807]
  304. *Staerk L, Gerds TA, Lip GYH, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 2018;283(1):45–55. Digital Object Identifier: 10.1111/joim.12683. PMID: 28861925. [PubMed: 28861925] [CrossRef]
  305. *Staerk L, Gislason GH, Lip GY, et al. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace 2015;17(8):1215–22. PMID: 25995392. [PubMed: 25995392]
  306. *Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol 2016;68(11):1169–78. PMID: 27609678. [PubMed: 27609678]
  307. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004;109(8):997–1003. PMID: 14967716. [PubMed: 14967716]
  308. Stoddard MF, Singh P, Dawn B, et al. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003;145(4):676–82. PMID: 12679765. [PubMed: 12679765]
  309. Stollberger C, Chnupa P, Abzieher C, et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol. 2004;27(1):40–6. PMID: 14743856. [PMC free article: PMC6654077] [PubMed: 14743856]
  310. Taillandier S, Olesen JB, Clementy N, et al. Prognosis in Patients with Atrial Fibrillation and CHA(2) DS(2) -VASc Score = 0 in a Community-Based Cohort Study. J Cardiovasc Electrophysiol. 2012;23(7):708–13. PMID: 22268375. [PubMed: 22268375]
  311. Tentschert S, Parigger S, Dorda V, et al. Recurrent vascular events in patients with ischemic stroke/TIA and atrial fibrillation in relation to secondary prevention at hospital discharge. Wien Klin Wochenschr. 2004;116(24):834–8. PMID: 15690967. [PubMed: 15690967]
  312. Tsivgoulis G, Spengos K, Zakopoulos N, et al. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. Age Ageing. 2005;34(1):35–40. PMID: 15591481. [PubMed: 15591481]
  313. *van den Ham HA, Klungel OH, Singer DE, et al. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. J Am Coll Cardiol 2015;66(17):1851–9. PMID: 26493655. [PubMed: 26493655]
  314. *van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6(4):740–7. PMID: 23723250. [PubMed: 23723250]
  315. Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9(1):39–48. PMID: 21029359. [PubMed: 21029359]
  316. *Vaughan Sarrazin MS, Jones M, Mazur A, et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014;127(12):1179–85. PMID: 25107386. [PMC free article: PMC7437526] [PubMed: 25107386]
  317. Vemmos KN, Tsivgoulis G, Spengos K, et al. Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. Am J Geriatr Pharmacother. 2004;2(4):265–73. PMID: 15903285. [PubMed: 15903285]
  318. Vemmos KN, Tsivgoulis G, Spengos K, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation-a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med. 2006;17(1):48–52. PMID: 16378886. [PubMed: 16378886]
  319. *Vemulapalli S, Hellkamp AS, Jones WS, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. Am Heart J 2016;178:74–84. PMID: 27502854. [PubMed: 27502854]
  320. *Verdecchia P, Reboldi G, Angeli F, et al. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace 2017. PMID: 28520924. [PMC free article: PMC5834147] [PubMed: 28520924]
  321. Viles-Gonzalez J, Kar S, Douglas P, et al. The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients with Atrial Fibrillation: A PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) Substudy. J Am Coll Cardiol. 2012;59(10):923–9. PMID: 22381428 [PubMed: 22381428]
  322. *Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015;114(6):1290–8. PMID: 26446456. [PubMed: 26446456]
  323. *Vinereanu D, Lopes RD, Mulder H, et al. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke 2017;48(12):3266–3273. Digital Object Identifier: 10.1161/strokeaha.117.017574. PMID: 29089455. [PubMed: 29089455] [CrossRef]
  324. *Vinereanu D, Stevens SR, Alexander JH, et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J 2015;36(46):3268–75. PMID: 26371113. [PubMed: 26371113]
  325. *Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013;127(22):2166–76. PMID: 23640971. [PubMed: 23640971]
  326. *Wang SV, Huybrechts KF, Fischer MA, et al. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2018. Digital Object Identifier: 10.1002/pds.4395. PMID: 29383858. [PubMed: 29383858] [CrossRef]
  327. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049–56. PMID: 12941677. [PubMed: 12941677]
  328. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116(22):2531–4. PMID: 17998456. [PubMed: 17998456]
  329. *Weir MR, Berger JS, Ashton V, et al. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. Curr Med Res Opin 2017:1–30. PMID: 28590785. [PubMed: 28590785]
  330. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41. PMID: 20694273. [PubMed: 20694273]
  331. *Westenbrink BD, Alings M, Granger CB, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2017;185:140–149. PMID: 28267467. [PubMed: 28267467]
  332. *Xu H, Ruff CT, Giugliano RP, et al. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc 2016;5(2). PMID: 26908401. [PMC free article: PMC4802446] [PubMed: 26908401]
  333. *Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation- An ENGAGE AF-TIMI 48 Subanalysis. Circ J 2016;80(4):860–9. PMID: 26888149. [PubMed: 26888149]
  334. *Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc 2016;5(6). PMID: 27412905. [PMC free article: PMC4937291] [PubMed: 27412905]
  335. *Yao X, Gersh BJ, Sangaralingham LR, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. Am J Cardiol 2017;120(9):1549–1556. Digital Object Identifier: 10.1016/j.amjcard.2017.07.051. PMID: 28844514. [PubMed: 28844514] [CrossRef]
  336. *Yarmohammadi H, Klosterman T, Grewal G, et al. Efficacy of the CHADS(2) scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation. Am J Cardiol 2013;112(5):678–83. PMID: 23726178. [PubMed: 23726178]
  337. Yigit Z, Kucukoglu MS, Okcun B, et al. The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn Heart J. 2003;44(3):369–77. PMID: 12825804 [PubMed: 12825804]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (5.8M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...